Valuation : Shield Therapeutics plc

Market Cap 5.88Cr 7.97Cr 6.85Cr 6.45Cr 11Cr 753.72Cr 11Cr 76Cr 30Cr 385.98Cr 30Cr 29Cr 1.23TCr P/E 2026 *
367x
P/E 2027 * 7.41x
Enterprise Value 7.73Cr 10Cr 9Cr 8.47Cr 14Cr 990.06Cr 15Cr 100.4Cr 39Cr 507.01Cr 39Cr 38Cr 1.61TCr EV / Sales 2026 *
1.45x
EV / Sales 2027 * 1.1x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Shield Therapeutics plc

1 day+10.55%
1 week+14.72%
Current month-0.33%
1 month+60.00%
3 months+1.33%
6 months-26.75%
Current year-38.27%
1 week 5.18
Extreme 5.18
6.4
1 month 3.76
Extreme 3.755
6.4
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Free

Chief Executive Officer

15,47,262 0.1485%
13/02/25 Free

Chief Executive Officer

50,00,000 0.4800%
13/02/25 Buy

Chief Executive Officer

5,75,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+10.55%+14.72%-23.04%-45.35% 7.96Cr
-1.87%+4.22%+44.36%+1.14% 8.27TCr
-0.76%+0.50%-17.24%-36.14% 6.02TCr
-2.23%+5.48%+478.96%+34.47% 5.81TCr
+1.31%-1.35%-7.43%+30.97% 4.97TCr
-0.14%-2.32%-0.05%+153.86% 4.67TCr
-1.64%+1.07%+56.98%-16.26% 3.26TCr
-0.98%+1.91%+46.30%+100.59% 2.57TCr
-1.07%-5.77%-1.75%+191.93% 2.27TCr
-1.06%+0.04%+63.04%+104.73% 1.65TCr
Average +0.23%-0.94%+64.01%+51.99% 3.95TCr
Weighted average by Cap. -0.98%+0.95%+86.42%+42.49%

Financials

2026 *2027 *
Net sales 5.35Cr 7.24Cr 6.23Cr 5.86Cr 10Cr 685.03Cr 10Cr 69Cr 27Cr 350.81Cr 27Cr 27Cr 1.12TCr 6.99Cr 9.47Cr 8.14Cr 7.66Cr 13Cr 895.54Cr 13Cr 91Cr 35Cr 458.61Cr 36Cr 35Cr 1.46TCr
Net income 3L 3L 3L 3L 5L 3.3Cr 5L 33.51L 12.95L 1.69Cr 13.12L 12.84L 5.39Cr 77.44L 1.05Cr 90.19L 84.83L 1.45Cr 99Cr 1.45Cr 10Cr 3.89Cr 51Cr 3.94Cr 3.85Cr 161.79Cr
Net Debt 1.85Cr 2.5Cr 2.15Cr 2.02Cr 3.45Cr 236.35Cr 3.46Cr 24Cr 9.26Cr 121.03Cr 9.39Cr 9.18Cr 385.53Cr 1.8Cr 2.44Cr 2.1Cr 1.97Cr 3.37Cr 230.52Cr 3.38Cr 23Cr 9.04Cr 118.05Cr 9.15Cr 8.95Cr 376.02Cr
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
07/26/07 GBX 6.080 +10.55% 13,48,465
04/26/04 GBX 5.500 -0.90% 14,79,928
03/26/03 GBX 5.550 -4.31% 14,04,908
02/26/02 GBX 5.800 +9.43% 32,80,463
01/26/01 GBX 5.300 -13.11% 1,17,69,677
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0550GBP
Average target price
0.1667GBP
Spread / Average Target
+203.04%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!